Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia- reperfusion injury

• Published in: Hepatobiliary & pancreatic diseases international Vol. 4; no. 3; pp. 350 - 355
• Main Authors: Lu, Ping, Liu, Fang, Yao, Zhong, Wang, Chun-You, Chen, Dao-Da, Tian, Yuan, Zhang, Jing-Hui, Wu, Yi-Hua
• Format: Journal Article
• Language: English
• Published: Singapore 01.08.2005
• Subjects: Adenosine Triphosphate - metabolism; Alanine Transaminase - blood; Allopurinol - pharmacology; Animals; Enzyme Inhibitors - pharmacology; Female; injury; ischemia-reperfusion; Liver - blood supply; Liver - metabolism; Male; NG-Nitroarginine Methyl Ester - pharmacology; nitric; Nitric Oxide - biosynthesis; Nitric Oxide - metabolism; Nitric Oxide Synthase - antagonists & inhibitors; nitrites; Nitrites - metabolism; oxide; Peroxidase - metabolism; Rats; Rats, Wistar; Reperfusion Injury - metabolism; Reperfusion Injury - pathology; Survival Analysis; Xanthine Dehydrogenase - antagonists & inhibitors; Xanthine Dehydrogenase - metabolism
• ISSN: 1499-3872

<正>It was demonstrated that xanthine oxidoreductase （XOR）, during ischemia, catalyzes the formation of nitric oxide （NO） from nitrite （NO2-） and this NO2--derived NO protects the isolated perfused rat heart against the damaging effects of ischemia-reperfusion （I/R） when conventional nitric oxide synthase （NOS） -dependent NO production is impaired. Liver is one of the organs with the highest XOR concentration. This study was designed to determine whether NO2--derived NO by XOR protects liver against I/R injury in vivo. For its minute amounts and active reactivity, NO can not be detected directly in real time in vivo by this time. We have to prove the above hypothesis indirectly. METHODS:Wistar rats were pretreated with saline, NOS inhibitor L-NAME （10 mg/kg intravenously）, XOR inhibitor allopurinol （1.5 mg/kg orally）, L-NAME +allopurinol and NO scavenger carboxy-PTIO （0.6 mg/kg intravenously） respectively （12 animals per group）. And then, they were subjected to total liver ischemia for 40 minutes followed by reperfusion. Blood samples and liver tissues were obtained for analysis after 3 hours of reperfusion. Survival was also investigated. RESULTS:Allopurinol-treated animals exhibited further increased serum alanine aminotransferase （ALT） levels and liver myeloperoxidase （MPO） activities, but further decreased liver adenosine triphosphate （ATP） stores after I/R compared to saline-treated counterparts （830.5±108.3 U/L, 56.5±11.0 U/mg protein and 1.93±0.47 μmol/g vs. 505.8± 184.2 U/L, 41.5±10.2 U/mg protein and 3.05±0.55 μmol/g respectively, P<0.01, P<0.05 and P<0.01 respectively）. The hepatocyte injury was further exacerbated and the overall survival rate was significantly decreased after I/R in animals given by allopurinol compared to those pretreated by saline （P<0.05）. L-NAME and allopurinol co-treated animals exhibited more severe liver injury （P<0.05 and P<0.01） and a further decreased overall survival rate （P<0.05） compared to L-NAME or allopurinol alone-treated counterparts, but they were not different from carboxy-PTIO treated animals （P>0.05）. CONCLUSION:NO2--derived NO by XOR in the hypoxic and acidic environment induced by hepatic I/R protects the liver against I/R injury in vivo.